231 - Outcomes by Baseline Pathogen and Susceptibility in the ReSTORE Phase 3 Trial of Rezafungin Once Weekly Compared with Caspofungin Once Daily in Patients with Candidemia and/or Invasive Candidiasis

Thursday, October 20, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Presenting Author(s)

George R. Thompson, III, MD

Professor
University of California Davis Medical Center
Sacramento, California, United States

AS

Alex Soriano, MD

Infectious Disease
Hospital Clínic de Barcelona
Barcelona, Catalonia, Spain
OC

Oliver A. Cornely, Prof. Dr.

Prof.
University of Cologne, Faculty of Medicine and University Hospital Cologne
Cologne, Nordrhein-Westfalen, Germany
BK

Bart-Jan Kullberg, MD, FRCP, FIDSA

Professor of Medicine
Radboud University Medical Center
Nijmegen, Gelderland, Netherlands
MK

Marin Kollef, MD

Doctor
Washington University, St. Louis Missouri
St Louis, Missouri, United States
JV

Jose A. Vazquez, MD

Augusta Univeristy
Augusta, Georgia, United States
AD

Anita F. Das, PhD

Cidara Therapeutics
San Dieog, California, United States
JL

Jeffrey B. Locke, PhD

Sr. Director Microbiology
Cidara Therapeutics
San Diego, California, United States
Taylor Sandison, MD, MPH (he/him/his)

Chief Medical Officer
Cidara Therapeutics
San Diego, CA, United States
PP

Peter G. Pappas, MD

University of Alabama at Birmingham
Birmingham, Alabama, United States